BioGaia AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0017769995
SEK
98.70
-1.15 (-1.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About BioGaia AB stock-summary
stock-summary
BioGaia AB
Pharmaceuticals & Biotechnology
Biogaia AB is a Sweden-based company engaged in the development and sell of probiotic products, primarily based on the Lactobacillus reuteri bacteria. The Company’s activities are divided into three segments: Finished consumer products, which distributes tablets, drops, Oral Rehydration Solutions (ORSs), and oral health products, among others; Component products, which is responsible for the sale of LifeTop Straw and Life Top Cap, as well as of cultures as an ingredient in licensee products, such as infant formula and dairy products; and Other products, including animal health goods. It collaborates with Nestle, Gerber, Delta Medical, InfectoPharmm, Ferring Middle East, AllergyCare, and Ewopharma, among others. Furthermore, the Company operates worldwide through a number of subsidiaries, such as Biogaia Biologics Inc, CapAble AB, TwoPac AB and Infant Bacterial Therapeutics AB.
Company Coordinates stock-summary
Company Details
Kungsbroplan 3 , STOCKHOLM None : 112 27
stock-summary
Tel: 46 8 5552930046 073 5001111
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Peter Rothschild
Chairman of the Board
Mr. David Dangoor
Independent Vice Chairman of the Board
Ms. Ewa Bjorling
Independent Director
Mr. Peter Elving
Independent Director
Ms. Inger Holmstrom
Independent Director
Mr. Anthon Jahreskog
Independent Director
Ms. Brit Stakston
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
405 Million
(Quarterly Results - Jun 2025)
Net Profit:
88 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 10,165 Million (Small Cap)

stock-summary
P/E

37.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

33.02%

stock-summary
Debt Equity

-0.60

stock-summary
Return on Equity

25.94%

stock-summary
Price to Book

8.35